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Lactobacilli versus antibiotics 
to prevent urinary tract 
infections: a randomized, double-
blind, noninferiority trial in 
postmenopausal women
Beerepoot et al., Arch Intern Med 2012; 172: 704–712; doi:10.1001/
archinternmed.2012.777
There is growing concern among family physicians and special-
ists alike about the development of resistant bacterial strains 
secondary to overuse of antibiotics. The development of these 
resistant strains is a particular concern in nephrology in the 
management of urinary tract infections (UTIs) in postmenopau-
sal women, in whom some of the natural defense mechanisms 
are no longer in effect. Beerepoot et al. studied non-antibiotic 
therapy (lactobacilli treatment prophylaxis) compared with 
antibiotics for recurrent UTIs in postmenopausal women. 
Two hundred fifty-two postmenopausal women with recur-
rent UTIs were randomized in a double-blind noninferiority 
trial to receive 12 months of prophylaxis with 480 mg trimeth-
oprim-sulfamethoxazole once daily or oral capsules contain-
ing lactobacillus twice daily. Primary end points were the mean 
number of symptomatic UTIs, the proportion of participants 
with at least one UTI during 12 months, the time to first UTI, 
and the development of antibiotic resistance by Escherichia coli. 
The authors reported that in comparison with the year prior 
to the trial, the mean number of UTIs was approximately 7 in 
both groups, whereas during the 12 months of the study the 
numbers were 2.9 for the antibiotic group and 3.3 for the yeast 
group. The between-treatment difference of 0.4 UTIs per year 
(95% confidence interval, –0.4 to 1.5) was outside the estimated 
noninferiority margin. At least one symptomatic UTI occurred 
in 69.3% and 79.1% of the trimethoprim-sulfamethoxazole 
and lactobacilli participants, respectively; median times to the 
first UTI were 6 and 3 months, respectively. After 1 month of 
trimethoprim-sulfamethoxazole prophylaxis, resistance to tri-
methoprim-sulfamethoxazole, trimethoprim, and amoxicillin 
had increased from 20% to 40% to 80% to 95% in E. coli from 
the feces and urine of asymptomatic women and among E coli. 
causing a UTI. In contrast, resistance was not increased during 
lactobacilli prophylaxis. The authors conclude that in postmeno-
pausal women with recurrent UTIs, lactobacilli therapy did not 
meet the noninferiority criteria in the prevention of UTIs com-
pared with trimethoprim-sulfamethoxazole.
Although this study was not able to demonstrate 
noninferiority to antibiotics, an important point to note is that 
the lactobacilli treatment did not increase antibiotic resistance, 
which suggests this therapy may be a suitable alternative to 
antibiotics, especially in patients in whom strain resistance has 
been previously demonstrated.
Daniel Cattran
Dependence of vascular 
calcification on vascular smooth 
muscle cell expression of Runx2
Sun et al., Circ Res 2012; 111: 543–552; doi:10.1161/CIRCRESAHA.112.267237
Vascular calcification is a major risk factor for cardiovascular 
morbidity and mortality, particularly in patients with athero-
sclerosis, diabetes, and/or chronic kidney disease. Many factors 
contribute to the pathogenesis of arterial calcification, either 
positively as promoters or negatively as inhibitors. The osteo-
genic runt-related transcription factor 2 (Runx2, also known 
as Cbfa1), which is essential for osteoblast differentiation and 
chondrocyte maturation, appears to be one of the major pro-
moters of vascular smooth muscle cell (VSMC) calcification, 
on the basis of previous experiments performed in vitro. Sun 
et al. now provide experimental evidence in vivo for the role of 
Runx2 in vascular calcification. They generated VSMC-specific 
Runx2-deficient mice in an apolipoprotein E–/– background, by 
breeding SM22a-Cre transgenic mice with Runx2 exon 8 floxed 
mice. Deletion of Runx2 exon 8 was verified by PCR analysis. 
The animals exhibited normal aortic gross anatomy and expres-
sion levels of VSMC-specific marker genes. Runx2 deficiency did 
not affect basal VSMC markers but inhibited oxidative stress-
reduced expression of these markers. High-fat diet-induced 
vascular calcification in vivo was markedly inhibited in the 
Runx2-deficient mice compared with their control littermates. 
Runx2 deficiency inhibited the expression of receptor activator 
of nuclear factor-kB ligand (RANKL), and this was accompa-
nied by decreased macrophage infiltration and formation of 
osteoclast-like cells in the calcified lesions. Coculture of VSMCs 
with bone marrow–derived macrophages demonstrated that 
the Runx2-deficient VSMCs failed to promote differentiation 
of macrophages into osteoclast-like cells. The Figure illustrates 
the functional contribution of Runx2 to vascular calcification.
Model for the functional contribution of Runx2 to vascular 
calcification. Oxidative stress induces the expression of Runx2 in VSMCs, 
which directly promotes osteogenic differentiation and calcification 
of VSMCs in vitro and in vivo. In addition, increased Runx2 directly 
upregulates the expression of receptor activator of nuclear factor-kB 
ligand (RANKL) in VSMCs by binding to the RANKL promoter, which in 
turn promotes infiltration of macrophages and formation of vascular 
osteoclasts in the calcified atherosclerotic lesions. Abbreviations: MΦ, 
macrophage; TRAP, tartrate-resistant acid phosphatase.
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These findings confirm the important role of osteogenic dif-
ferentiation of VSMCs in arterial calcification. They further 
demonstrate a major role of Runx2 not only in this process, 
but also in promoting macrophage infiltration into calcified 
atherosclerotic lesions and RANKL-mediated macrophage 
differentiation into osteoclast-like cells. The function of these 
cells found in the vicinity of calcified areas is not yet clear. 
From a clinical point of view, targeting Runx2 or Runx2-reg-
ulating signals in VSMCs may represent a novel strategy for 
prevention and therapy of vascular calcification.
Tilman B. Drüeke
Association of provider–patient 
visit frequency and patient 
outcomes on hemodialysis
Slinin et al., J Am Soc Nephrol 2012; 23: 1560–1567; doi:10.1681/
ASN.2012010051
Hemodialysis mortality rates vary both within and between 
countries, and this disparity has led to speculation about 
whether different models of medical supervision and practice 
affect outcomes. Practices vary quite markedly, from very fre-
quent medical review at each dialysis session to monthly or 
even less frequent review in the dialysis center, coupled with 
formal 6-month or annual clinic reviews. The proponents of 
more frequent review in the dialysis center have argued that 
greater doctor–patient contact could improve both dietary and 
medication compliance and limit intradialytic weight gains, 
with improved blood pressure and phosphate control. In the 
United States, the standard approach had been monthly review 
of all patients in dialysis centers, but the introduction of addi-
tional payments for more frequent medical review led many 
centers to increase to weekly medical review. Slinin and col-
leagues analyzed outcomes from patient data submitted to the 
US Renal Data System database, comparing cohorts of patients 
reviewed monthly or more frequently. Patients reviewed less 
frequently were more likely to be younger, Caucasoid, of lower 
socioeconomic status, and of rural residence, and, during the 
run-in pre-study period, more likely to miss dialysis sessions 
and less likely to have been hospitalized. More frequent review 
did not improve either raw or adjusted 1-year patient mortal-
ity. However, after adjustment, first and repeated admissions 
were marginally, but significantly, reduced with more frequent 
review. Although the differences were small, this finding would 
translate into considerable health-care cost savings.
Whether doctor–patient consultation duration and quality 
were similar with more frequent review is unknown, and simi-
larly, surrogates of the quality of care delivered, such as dialysis 
attendance, intradialytic weight gains, blood pressure, and phos-
phate control, were not reported. However, since the change in 
reimbursement policy and more frequent medical review, the 
hospital admission rate of US dialysis patients has decreased.
Andrew Davenport
Unraveling the chemistry of the 
glomerular basement membrane
Bhave et al., Nat Chem Biol 2012; 8: 784–790; doi:10.1038/nchembio.1038
The structure and function of type IV collagen within the glo-
merular basement membrane (GBM) are crucial to normal 
GBM function; thus, understanding how the component col-
lagen strands are assembled is important for understanding 
glomerular function in health and disease. It has been known 
that type IV collagen is assembled from protomers. The bind-
ing of the C-terminals of the protomers occurs by intermo-
lecular sulfilimine cross-links. Disruption of these sulfilimine 
bonds allows exposure of the collagen type IV epitopes to the 
immune system as the target autoantigens in Goodpasture’s 
syndrome. Up until now, the molecular mechanism allowing 
these unusual chemical bonds to form has been unknown. 
Using a Drosophila-based system, Bhave et al. have identified 
an orphan enzyme, of previously unknown function, that is 
present in the GBM as the enzyme responsible for the forma-
tion of these bonds. The enzyme peroxidasin was originally 
identified as a basement membrane protein in Drosophila in 
1994, but its function until now has been unknown. The inves-
tigators used a mouse endodermis cell line that produces small 
quantities of collagen IV and forms basement membrane in 
vitro. Using this cell culture system in the presence or absence 
of peroxidase inhibitors, Bhave and colleagues identified the 
existence of an endogenous peroxidase within the basement 
membrane that forms these sulfinimide bonds. This enzyme 
was subsequently shown to be peroxidasin, which is active 
under oxidative conditions. To confirm the role of this enzyme 
in vivo, Drosophila peroxidasin (Pxn) mutant larvae were gen-
erated, which show distorted collagen IV in the heterozygote 
(Pxn+/–) and complete-knockout (Pxn–/–) animals compared 
with wild type (Pxn+/+) (Figure). Taken together, these novel 
findings on the chemistry of the GBM move us still closer to 
understanding normal GBM function and, potentially, how the 
Goodpasture antigen becomes exposed in disease.
P. Toby Coates
Peroxidasin is critical for collagen IV and basement membrane 
integrity. (a) Confocal fluorescence microscopy images of Drosophila 
anterior midgut using a collagen IV GFP protein trap line (vikingG454) to 
delineate collagen IV distribution. Representative sections from wild-type 
Pxn+/+, heterozygote Pxn+/− (Pxn+/f07229), and mutant Pxn−/− (Pxnf07229/f07229) 
flies are shown. Distorted and torn collagen IV networks (arrows) with gross 
defects (‘holes’) in the circumferential muscle layer (asterisks) typified Pxn−/− 
sections. Scale bars, 10 mm. (b) Immunoblot of collagenase-solubilized 
basement membrane isolated from Drosophila Pxn+/− and Pxn−/− larvae.
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